Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAMA-1 | HR+ | Luminal | Celecoxib | COX2 | COX | 0.0213 | uM | 10473.136 | 0.9678 | 0.9509 | 1.3186 | |
| CAMA-1 | HR+ | Luminal | Celecoxib | COX2 | COX | 0.107 | uM | 10473.136 | 0.9156 | 0.8706 | 1.3186 | |
| CAMA-1 | HR+ | Luminal | Celecoxib | COX2 | COX | 0.533 | uM | 10473.136 | 0.9774 | 0.9657 | 1.3186 | |
| CAMA-1 | HR+ | Luminal | Celecoxib | COX2 | COX | 2.67 | uM | 10473.136 | 1.0018 | 1.0027 | 1.3186 | |
| CAMA-1 | HR+ | Luminal | Celecoxib | COX2 | COX | 13.3 | uM | 10473.136 | 0.9459 | 0.9175 | 1.3186 | |
| CAMA-1 | HR+ | Luminal | Celecoxib | COX2 | COX | 66.7 | uM | 10473.136 | 0.9248 | 0.8849 | 1.3186 | |
| CAMA-1 | HR+ | Luminal | Celecoxib | COX2 | COX | 333 | uM | 10473.136 | 0.9650 | 0.9467 | 1.3186 | |
| CAMA-1 | HR+ | Luminal | Celecoxib | COX2 | COX | 1670 | uM | 10473.136 | 1.0867 | 1.1301 | 1.3186 | |
| HCC1187 | TNBC | Basal A | Celecoxib | COX2 | COX | 0.00427 | uM | 10518.136 | 0.9331 | 0.8921 | 1.2490 | |
| HCC1187 | TNBC | Basal A | Celecoxib | COX2 | COX | 0.0213 | uM | 10518.136 | 0.9879 | 0.9806 | 1.2490 | |
| HCC1187 | TNBC | Basal A | Celecoxib | COX2 | COX | 0.107 | uM | 10518.136 | 0.9788 | 0.9660 | 1.2490 | |
| HCC1187 | TNBC | Basal A | Celecoxib | COX2 | COX | 0.533 | uM | 10518.136 | 1.0492 | 1.0784 | 1.2490 | |
| HCC1187 | TNBC | Basal A | Celecoxib | COX2 | COX | 2.67 | uM | 10518.136 | 1.0767 | 1.1219 | 1.2490 | |
| HCC1187 | TNBC | Basal A | Celecoxib | COX2 | COX | 13.3 | uM | 10518.136 | 0.9779 | 0.9646 | 1.2490 | |
| HCC1187 | TNBC | Basal A | Celecoxib | COX2 | COX | 66.7 | uM | 10518.136 | 0.9931 | 0.9889 | 1.2490 | |
| HCC1187 | TNBC | Basal A | Celecoxib | COX2 | COX | 333 | uM | 10518.136 | 0.9436 | 0.9091 | 1.2490 | |
| HCC1187 | TNBC | Basal A | Celecoxib | COX2 | COX | 1670 | uM | 10518.136 | 0.9607 | 0.9369 | 1.2490 | |
| HCC3153 | TNBC | Basal A | Celecoxib | COX2 | COX | 0.00427 | uM | 10577.136 | 0.9162 | 0.8319 | 0.9962 | |
| HCC3153 | TNBC | Basal A | Celecoxib | COX2 | COX | 0.0213 | uM | 10577.136 | 0.9284 | 0.8562 | 0.9962 | |
| HCC3153 | TNBC | Basal A | Celecoxib | COX2 | COX | 0.107 | uM | 10577.136 | 0.9529 | 0.9055 | 0.9962 | |
| HCC3153 | TNBC | Basal A | Celecoxib | COX2 | COX | 0.533 | uM | 10577.136 | 0.9482 | 0.8960 | 0.9962 | |
| HCC3153 | TNBC | Basal A | Celecoxib | COX2 | COX | 2.67 | uM | 10577.136 | 0.9539 | 0.9074 | 0.9962 | |
| HCC3153 | TNBC | Basal A | Celecoxib | COX2 | COX | 13.3 | uM | 10577.136 | 0.9228 | 0.8450 | 0.9962 | |
| HCC3153 | TNBC | Basal A | Celecoxib | COX2 | COX | 66.7 | uM | 10577.136 | 0.9391 | 0.8777 | 0.9962 | |
| HCC3153 | TNBC | Basal A | Celecoxib | COX2 | COX | 333 | uM | 10577.136 | 0.9220 | 0.8434 | 0.9962 |